HUMAX-CD4 STUDY

Genmab A/S presented data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th annual meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score.

Related Videos
Related Content

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.